Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Filgotinib

Filgotinib

An immunology drug developed by Galapagos and licensed to Gilead Sciences for the treatment of rheumatoid arthritis

Filgotinib is an immunology drug developed by Galapagos and licensed to Gilead for the treatment of rheumatoid arthritis. Filgotinib has been evaluated in multiple late-stage clinical studies, demonstrating efficacy and safety. The drug is also being evaluated by Gilead for other autoimmune indications like Crohn’s disease, psoriatic arthritis and ulcerative colitis. Galapagos plans to have greater involvement in European commercialization of Filgotinib and split the development costs with Gilead.

Timeline

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
BioSpace
June 5, 2020
BioSpace
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with psoriatic arthritis (PsA). The data from the dou

References

Golden logo
By using this site, you agree to our Terms & Conditions.